Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: Animal Models of Alzheimer's Disease: Therapeutic Implications
Guest editors: Diana Woodruff-Pak
Article type: Research Article
Authors: Buccafusco, Jerry J.a; b; *
Affiliations: [a] Alzheimer's Research Center, Medical College of Georgia, Augusta, GA, USA | [b] Charlie Norwood VA Medical Center, Augusta, GA, USA
Correspondence: [*] Address for correspondence: Jerry J. Buccafusco, Ph.D., Director, Alzheimer's Research Center, Medical College of Georgia, Augusta, GA 30912-2300, USA. Tel.: +1 706 721 6355; Fax: +1 706 721 9861; E-mail: jbuccafu@mcg.edu.
Abstract: Non-human primates have served as subjects for studies of the cognition-enhancing potential of novel pharmacological agents for over 25 years. Only recently has a greater appreciation of the translational applicability of this model been realized. Though most Old-World monkeys do not appear to acquire an Alzheimer's-like syndrome in old age, their value resides in the brain physiology they have in common with humans. Paradigms like the delayed matching-to-sample task engender behavior that models aspects of working memory that are substrates for the actions of cognition-enhancing drugs. Our studies have provided information relevant to factors that limit the effectiveness of clinical trial design for compounds that potentially improve cognition. For example, cognition-enhancing compounds from different pharmacological classes, when administered to monkeys, can exhibit remarkable pharmacodynamic effects that outlast the presence of the drug in the body. Studies with non-human primates also can provide information regarding dose ranges and individual subject sensitivity experienced in the clinic. Components of working memory are differentially sensitive to drug effects and may be characterized by different dose ranges for certain compounds, even within the same task. Examples are provided that underscore the possible idiosyncrasies of drug action in the pharmacology of cognition – which could be of critical importance in the design of clinical trials.
Keywords: Acetylcholinesterase inhibition, aging, Alzheimer's disease, attention deficit disorder, delayed matching, drug development, nicotinic acetylcholine receptors, non-human primates, working memory
DOI: 10.3233/JAD-2008-15414
Journal: Journal of Alzheimer's Disease, vol. 15, no. 4, pp. 709-720, 2008
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl